Mesoblast is a global leader in the field of regenerative medicine. The Company has established a clinically advanced and diverse portfolio of cell-based therapeutics, with five programs in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. These clinical programs target areas with significant unmet medical needs including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.
Our proprietary technology platform is based on mesenchymal lineage adult stem cells (MLCs) and underpins all our therapeutic products. Our lead product candidates include MPC-150-IM for congestive heart failure, MPC-06-ID for chronic lower back pain due to moderate degenerative disc disease, MSC-100-IV for steroid refractory acute graft versus host disease (GVHD), and MPC-300-IV for biologic refractory rheumatoid arthritis, and diabetic nephropathy.
All our products are allogenic or "off-the-shelf", meaning stem cells from a young, healthy adult donor can be expanded and used in many unrelated patients without the need for tissue matching. Our proprietary manufacturing processes are designed to enable production at commercial scale with reproducibility and batch-to-batch consistency.
Our portfolio of MLC-derived product candidates each has its own distinct technical characteristics, target indications, individual reimbursement strategy, separate commercialization potential, and unique partnering opportunities.
Led by Chief Executive Professor Silviu Itescu, a pioneer of stem cell therapeutics, the Mesoblast management team has substantial experience in all aspects of biopharmaceutical development. There are approximately 120 employees, primarily in the United States, and also in Australia and Singapore.
Mesoblast was publicly listed on the Australian Securities Exchange (ASX:MSB) in 2004. A Level 1 American Depositary Receipt (ADR) program facility trading in the Over-The-Counter (OTC) market in the United States has been established (OTC:MBLTY).